Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy

Markus Hoffmann, a,b Anzhalika Sidarovich, a,b Prerna Arora, a,b Nadine Krüger, a Inga Nehlmeier, a Amy Kempf, a,b Luise Graichen, a,b Martin S. Winkler, c Daniela Niemeyer, d,e Christine Goffinet, d Christian Drosten, d,e Sebastian Schulz, f Hans-Martin Jäck, f Stefan Pöhlmann a,b

a Infection Biology Unit, German Primate Center, Göttingen, Germany
b Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany
c Department of Anesthesiology, University of Göttingen Medical Center, and Georg-August University of Göttingen, Göttingen, Germany
d Institute of Virology, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany
e German Centre for Infection Research, associated partner Charité, Berlin, Germany
f Division of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany

ABSTRACT SARS-CoV-2 variants of concern (VOC) acquired mutations in the spike (S) protein, including E484K, that confer resistance to neutralizing antibodies. However, it is incompletely understood how these mutations impact viral entry into host cells. Here, we analyzed how mutations at position 484 that have been detected in COVID-19 patients impact cell entry and antibody-mediated neutralization. We report that mutation E484D markedly increased SARS-CoV-2 S-driven entry into the hepatoma cell line Huh-7 and the lung cell NCI-H1299 without augmenting ACE2 binding. Notably, mutation E484D largely rescued Huh-7 but not Vero cell entry from blockade by the neutralizing antibody Imdevimab and rendered Huh-7 cell entry ACE2-independent. These results suggest that the naturally occurring mutation E484D allows SARS-CoV-2 to employ an ACE2-independent mechanism for entry that is largely insensitive against Imdevimab, an antibody employed for COVID-19 therapy.

IMPORTANCE The interaction of the SARS-CoV-2 spike protein (S) with the cellular receptor ACE2 is considered essential for infection and constitutes the key target for antibodies induced upon infection and vaccination. Here, using a surrogate system for viral entry, we provide evidence that a naturally occurring mutation can liberate SARS-CoV-2 from ACE2-dependence and that ACE2-independent entry may protect the virus from neutralization by an antibody used for COVID-19 therapy.

KEYWORDS ACE2, COVID-19, antibody, neutralization, spike

The spike (S) protein of SARS-CoV-2 mediates entry into host cells and is the key target for neutralizing antibodies induced upon infection and vaccination or used for COVID-19 therapy (1). The S proteins of SARS-CoV-2 variants of concern (VOC) harbor mutations that reduce susceptibility to antibody-mediated neutralization and may alter virus-host cell interactions (2). Amino acid residue E484 is located in the receptor binding domain (RBD) of the S protein (Fig. 1a), which binds to the cellular receptor ACE2, and VOCs Beta (B.1.351) and Gamma (P.1), harbor mutation E484K, which has been associated with neutralization resistance (2, 3). However, a systematic comparison of the role of amino acid residue 484 in antibody-mediated neutralization and host cell entry is so far lacking.

E484D INCREASES ENTRY INTO HUH-7 CELLS

We employed rhabdoviral pseudotypes, which faithfully mimic SARS-CoV-2 entry into cells and its inhibition by antibodies (4), to analyze the role of amino acid residue 484 in host cell entry and its inhibition (see material and methods in the supplement). The analysis...
FIG 1 Spike mutation E484D leads to cell line-dependent enhancement of infection in a potentially ACE2-independent manner and allows escape from neutralization by Imdevimab. (a) Spike (S) protein scheme (abbreviations: RBD = receptor binding domain, TD = transmembrane domain) and location of residue E484 in the context of the three-dimensional S protein structure (color code: Light blue = S1 subunit [non-RBD], dark blue = RBD, gray = S2 subunit, red = residue E484). (b) Frequency of mutations at S protein residue E484 (letters indicate amino acid exchanges, single letter code). The dashed line shows the threshold for selection of mutants for in-depth analysis (minimum frequency = 75 entries in the GISAID database as of 29.09.2021). (c) Mutations at position E484 lead to cell line-dependent augmentation of infection. Particles pseudotyped with the indicated S proteins were inoculated onto H1299 (human, lung) and Huh-7 (human, liver) cells. At 16–18h postinoculation, transduction efficiency was analyzed by measuring virus-encoded luciferase activity in cell lysates. Presented are the average (mean) data from three biological replicates (each conducted with four technical replicates), for which transduction was normalized against wild-type (WT) SARS-CoV-2 S (set as 1). Error bars indicate the standard error of the mean (SEM). (d) Mutation E484D enables evasion from Imdevimab-mediated neutralization in Huh-7 but not Vero cells. Particles pseudotyped with the indicated S proteins were preincubated (30 min, 37°C) with different concentrations of monoclonal antibodies used for COVID-19 therapy (Casirivimab, Imdevimab, Bamlanivimab, (Continued on next page)
of SARS-CoV-2 sequences deposited in GISAID (as of 29.09.2021) revealed that the most frequent substitution at position 484 is E484K, followed by E484Q, E484A, E484D, and E484G (Fig. 1b). We introduced these substitutions into the S protein of B.1 (which is identical to the S protein of the Wuhan-01 isolate except for mutation D614G) and analyzed entry into a diverse panel of cell lines. None of the mutations appreciably altered binding to soluble ACE2 (Fig. S1a). The mutations did not enhance entry into 293T, BEAS-2B, Caco-2, Calu-3, and Vero cells but some mutations caused a moderate decrease in cellular entry (Fig. S1b). In contrast, mutation E484D moderately increased entry into A549, HOS and NCI-H727 cells (Fig. S1c) and markedly augmented entry into NCI-H1299 and Huh-7 cells (Fig. 1c and Fig. S1d). Further, mutations E484Q, E484A, E484G and particularly E484K also increased entry into NCI-H1299 cells (Fig. 1c), indicating that amino acid residue 484 may modulate viral cell tropism.

**E484D RENDERS HUH-7 CELL ENTRY LESS SENSITIVE TO IMDEVIMAB**

We next hypothesized that the increased Huh-7 cell entry of mutant E484D might reflect altered interactions with entry factors which, in turn, might be associated with altered neutralization by antibodies. To address this possibility, we compared neutralization using Vero (which allowed comparable entry of all mutants tested) and Huh-7 cells (which allowed for increased entry of mutant E484D) as target cells. Neutralization by convalescent plasma revealed that mutation E484K, which is present in VOCs Beta and Gamma, and mutation E484Q, found in the variant of interest Kappa (B.1.617.1), markedly reduced neutralization sensitivity, in keeping with published data (2, 3), while the other mutations had minor or no effects (Fig. S2a-b). No appreciable differences were observed when Vero or Huh-7 cells were used as targets (Fig. S2a-b). We next analyzed neutralization by antibodies employed for COVID-19 therapy. All mutations studied were compatible with neutralization by Casirivimab, although minor differences in neutralization sensitivity were noted, and Etesevimab (Fig. 1d). In contrast, all mutations studied reduced or abrogated neutralization by Bamlanivimab, as expected, since E484 resides in the center of the epitope recognized by this antibody (Fig. S2c), and the results were independent of the target cell line used (Fig. 1d). Surprisingly, exchange E484D protected from Imdevimab-mediated neutralization in Huh-7 but not Vero cells (Fig. 1d), although the antibody epitope is located distantly from the mutated residue (Fig. S2c) and Imdevimab binding to the S protein was not compromised by mutation E484D (Fig. S2d). This finding suggests that mutant E484D may utilize an altered strategy for entry into Huh-7 cells that is associated with reduced sensitivity to neutralization by certain antibodies.

**E484D ALLOWS FOR ACE2-INDEPENDENT ENTRY INTO HUH-7 CELLS**

We next thought to gain initial insights into how mutant E484D enters Huh-7 cells. We found that soluble ACE2 robustly and comparably blocked Vero and Huh-7 cell entry of WT and mutant E484D (Fig. S3a). In contrast, mutant E484D was largely resistant against inhibition by two antibodies raised against the ACE2 ectodomain (Fig. 1e and Fig. S3b). Specifically, the antibodies efficiently blocked WT entry into Vero and Huh-7 cells but exerted...
little (Vero) or no (Huh-7) inhibitory activity against mutant E484D (Fig. 1e and Fig. S3b). Thus, mutation E484D might either markedly alter S protein interactions with ACE2, rendering entry resistant to the ACE2-antibodies employed in the present study, or might allow for ACE2-independent entry, as demonstrated by a separate study focusing on the cell line H522 (5), or both. Next, we asked whether engagement of heparan sulfate proteoglycans, which can augment SARS-CoV-2 infection (6, 7), promoted entry into Huh-7 cells. Vero cells were used as reference. Preincubation of S protein-bearing particles with soluble heparin moderately and comparably reduced WT and E484D entry into Vero cells (Fig. 1f). Inhibition of entry was more pronounced in Huh-7 cells and mutant E484D was slightly more efficiently inhibited compared to WT (Fig. 1f). Thus, heparan sulfate-containing proteoglycans might partially account for the increased Huh-7 cell entry of E484D, as suggested by a separate study for H522 cells (5) but are unlikely to be the only explanation.

**DISCUSSION**

As of 29.09.2021, mutation E484D has been reported globally in a total of 105 out of 3,798,740 SARS-CoV-2 sequences deposited in the GISAID (Global Initiative on Sharing All Influenza Data) database with increasing frequency in 2021 and is associated with multiple SARS-CoV-2 lineages (Fig. S4a-c). Our results show that mutation E484D increases entry into Huh-7 cells, which is associated with altered or, perhaps more likely, abrogated ACE2 usage and Imdevimab resistance. These findings await confirmation with authentic SARS-CoV-2 but are in keeping with a previous study showing that mutation E484D allowed ACE2-independent entry of authentic SARS-CoV-2 into the lung cell line H522, as demonstrated by ACE2 expression (not detected in H522 cells), antibody inhibition and ACE2 knockout analyses (5). Further, the study demonstrated that entry into H522 cells, although being ACE2-independent, was highly susceptible to blockade by soluble ACE2 and antibodies directed against the RBD and the N-terminal domain (NTD) of the S protein (5). The presence of an ACE2-independent pathway operative in certain cell lines raises interesting questions mainly regarding the nature of the cellular factor(s) that allow S protein-mediated viral attachment to target cells but also regarding the enzymes exploited for proteolytic activation of the S protein. The present study and previous work (5) suggest that mutant E484D is activated by the endolysosomal protease cathepsin L (Fig. S5a) and exploits HSPG but not neuropilin-1 for ACE2-independent entry. However, HSPG usage is unlikely to be solely responsible for the ACE2-independent Huh-7 cell entry of mutant E484D, considering that entry inhibition by heparin was incomplete. The cellular lectin ASGR1 is expressed by Huh-7 cells and has recently been reported to serve as alternative SARS-CoV-2 receptor (8). Therefore, future studies should examine whether ASGR1 contributes to Huh-7 cell entry of mutant E484D. Another receptor candidate to be considered is activated integrin α5β1, which was also recently shown to allow for ACE2-independent entry (9).

Mutation E484D did not interfere with binding of the antibody Imdevimab to the S protein but selectively conferred resistance to neutralization by Imdevimab in Huh-7 cells, suggesting that the Imdevimab epitope is dispensable for use of the postulated alternative (i.e., ACE2-independent) entry route. In contrast, Casirivimab and Etesevimab neutralized both Vero and Huh-7 cell entry with high efficiency, indicating that the epitopes recognized by Casirivimab and Etesevimab are required for entry via both the “conventional” (ACE2-dependent) and the alternative (ACE2-independent) route. Whether the cell type-dependent effect of E484D on neutralization sensitivity has implications for viral control by antibodies in the host is unknown. The notion that E484D can emerge upon adaptation of SARS-CoV to growth in cell culture (10) and may increase sensitivity toward the SARS-CoV-2 restriction factors IFITM2/IFITM3 (11, 12), as determined by augmentation of entry upon amphotericin B treatment (Fig. S5b), argues against an important role in vivo. On the other hand, mutation E484D (13) and SARS-CoV-2 infection of liver (14) has been detected in COVID-19 patients and ACE2-independent infection of liver cells might contribute to viral pathogenesis. Finally, it is noteworthy that several substitutions of residue E484, including the frequently occurring E484K present in VOCs Beta and Gamma, increased entry into the lung cell line NCI-H1299, which allowed for augmented entry of particles bearing S proteins of VOC compared to WT
S protein (Fig. 5c). Thus, analysis of the mechanisms underlying increased VOC entry into H1299 cells could yield valuable insights into why VOC outcompete previously circulating viruses.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

REFERENCES

1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 182:271–280. https://doi.org/10.1016/j.cell.2020.02.052.
2. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Consortium C-GU, Peacock SJ, Robertson DL, COVID-19 Genomics UK (COG-UK) Consortium. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409–424. https://doi.org/10.1038/s41579-021-00573-0.
3. Liu Z, Vandliergan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, Alford B, Buchler WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ. 2021. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29:477–488. https://doi.org/10.1016/j.chom.2021.01.014.
4. Schmidt F, Weisblum Y, Muecksz H, Hoffmann HH, Michaelidis E, Lorenzi JC, Mendoza P, Rutkowski M, Bednarz E, Gaeberl C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M, Caskey M, Robbiani DF, Nussenzweig MC, Rice CM, Hatziioannou T, Bienasz PD. 2020. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 217:e20201181. https://doi.org/10.1084/jem.20201118.
5. Puray-Chavez M, LaPak KM, Schrank TP, Ellison JL, Bhatt DP, Agajanian MJ, Jasuja R, Lawson DO, Davis K, Rothlauf PW, Liu Z, Jo H, Lee N, Tennen K, Eschbach JE, Shema Mugisha C, Cousins EM, Cleow EW, Vuong HR, Vandliergan LA, Bailey AL, Gichuk P, Crowe JE, Jr, Diamond MS, Hayes DN, Whelan SPJ, Horani A, Brody SL, Goldfarb D, Major MB, Kutlay SB. 2021. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell Rep 36:109364. https://doi.org/10.1016/j.celrep.2021.109364.
6. Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanana A, Majowicz SA, Kwong EM, Miccaro RN, Thacker BE, Glass CA, Yang Z, Torres JL, Golden GJ, Bartels PL, Porell RN, Garreton AF, Laubach L, Feldman J, Yin X, Pu Y, Hauser BM, Caradonna TM, Kelman BP, Martino C, Groths P, Chanda SK, Schmidt AG, Godula K, Leibl SL, Jose J, Corbett KD, Ward AB, Carlin AF, Esko JD. 2020. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183:1043–1057. https://doi.org/10.1016/j.cell.2020.09.033.
7. Zhang Q, Chen CZ, Swaroop M, Xu M, Wang L, Lee J, Wang AQ, Pradhan M, Hagen N, Chen L, Shen M, Luo Z, Xu X, Xu Y, Huang W, Zheng W, Ye Y. 2020. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov 6:80. https://doi.org/10.1038/s41421-020-00222-5.
8. Gu Y, Cao J, Zhang X, Gao H, Wang Y, Wang J, He J, Jiang X, Zhang J, Shen G, Yang J, Zheng X, Hu G, Zhu Y, Du S, Zhu Y, Zhang R, Xu J, Lan F, Qu D, Xu G, Zhao Y, Gao D, Xie Y, Luo M, Lu Z. 2022. Receptor profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Res 32:34–37. https://doi.org/10.1038/s41422-021-00595-6.
9. Liu J, Lu F, Chen Y, Plow E, Qin J. 2022. Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2. J Biol Chem 298:107170. https://doi.org/10.1016/j.jbc.2022.107170.
10. Ramirez S, Fernandez-Antunez C, Galli A, Underwood A, Pham LV, Ryberg LA, Feng S, Pedersen MS, Mikkelsen LS, Belouzard S, Dubuisson J, Solund C, Weiss N, Gottwein JM, Fahmoe U, Buhk J. 2021. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication. Antiviral Agents Chemother 65:e0009721. https://doi.org/10.1128/AAC.00097-21.
11. Peacock TP, Goldhill DH, Zhou J, Baillon L, Frisse R, Swann OC, Kugathasan R, Penn R, Brown JC, Sanchez-David RY, Braga L, Williamson MK, Hassard JA, Staller E, Hanley B, Osborn M, Gicca M, Davidson AD, Matthews DA, Barclay WS. 2021. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat Microbiol 6:899–909. https://doi.org/10.1038/s41564-021-00908-w.
12. Winstone H, Lista MJ, Reid AC, Bouton C, Pickering S, Galao RP, Kerridge C, Doores KJ, Swanson CM, Neill SJD. 2021. The polybasic cleavage site in SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2. J Virol 95. https://doi.org/10.1128/JVI.02422-20.
13. Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M, Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Aepfelbacher M, Huber TB. 2020. Multiorgan and renal tropism of SARS-CoV-2 variants in Houston, Texas, January through May 2020. Engl J Med 383:590–592. https://doi.org/10.1056/NEJMoa210400.

ACKNOWLEDGMENTS

We thank G. Zimmer, A. Maisner, and S. Ludwig for providing reagents and the anonymous reviewers for their helpful comments. S.P. acknowledges funding by BMBF (01KI2006D, 01KI20328A, 01KI20396, 01KI2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MVK HZI COVID-19) and the German Research Foundation (DFG; PO 716/11-1, PO 716/14-1). N.K. was supported by BMBF (01KI2074A). M.S.W. received unrestricted funding (14-76103-184, MWK HZI COVID-19) and the German Research Foundation (DFG; PO 716/11-1, PO 716/14-1). M.S.W. received funding from Sartorius AG, Lung research. H.-M.J. received funding from BMBF (01KI2043, 01KI2021), Bavarian State Ministry for Science and the Arts and Deutsche Forschungsgemeinschaft (DFG) through the research training groups RTG1660 and TRR130.

We have no conflicts of interest to declare.

ACS Project 13 Issue 3

May/June 2022 Volume 13 Issue 3 10.1128/mBio.00364-22

S. P. J. Ackerman

ACE2-Independent SARS-CoV-2 Entry

mBio

n. T. A. B. N. D. C. E.